Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Regeneron bets up to $2.3 billion on new targeted drug technology

Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Editorial illustration

Summary

Pharmaceutical giant Regeneron is teaming up with Parabilis Medicines in a massive new partnership that could eventually be worth up to $2.3 billion. To kick off the collaboration, Regeneron is putting down $125 million in a mix of cash and equity investments. Their shared goal is to create a brand new class of targeted medications.

The companies are focusing on a new spin on antibody-drug conjugates, often called ADCs. Traditional ADCs work somewhat like guided missiles. They use specialized proteins called antibodies to seek out specific diseased cells, delivering a potent drug directly to the target. This new partnership aims to design a novel ADC-like therapy. The researchers hypothesize that this updated technology will be able to firmly bind to tricky cellular targets that existing options struggle to reach.

While the financial backing is substantial, scientists are just getting started. These experimental therapies are still in the very earliest stages of discovery and development. At this point, the researchers have not reported any clinical data showing whether the new treatments are safe or effective in patients.

Why it matters.

Finding ways to deliver powerful medicines directly to diseased cells without harming healthy tissue is one of the biggest challenges in modern medicine. If this new technology works as hypothesized, it could open the door to treating complex conditions that have successfully evaded older therapies. By improving how well a drug binds to a challenging target site, doctors could potentially treat patients more effectively and with greater precision.

The sheer size of this potential $2.3 billion deal highlights how valuable this technology is to the pharmaceutical industry. Regeneron is willing to risk an initial $125 million because of the massive potential payoff of reaching difficult disease targets. Even though human trials are a long way off, this partnership signals a major financial commitment to the future of targeted drug development.

From the source

The story in numbers.

Total potential deal value
$2.3B
Upfront cash and equity investment
$125 million
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Regeneron bets up to $2.3 billion on new targeted drug technology — Daily Strand